{"entity":{"id":"nct05914116","kind":"trial","name":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of BNT324 and Enzalutamide in advanced solid tumours, run by DualityBio Inc., now recruiting.","summary":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05914116 by DualityBio Inc., with 862 participants planned, started 2023-08-17 and due to reach its primary completion in 2027-12. Interventions recorded: DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide and Abiraterone.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05914116","url":"https://clinicaltrials.gov/study/NCT05914116"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["bnt324","enzalutamide"],"companies":["dualitybio","biontech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05914116","phase":"1/2","setting":"A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors","sponsor":"DualityBio Inc.","enrolled":862,"outcomes":[]},"route":"/trials/nct05914116/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"bnt324","kind":"drug","name":"BNT324","route":"/drugs/bnt324/"},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"},{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","route":"/companies/dualitybio/"}]}}